Marinus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Marinus Pharmaceuticals

10/08/2023 16:06

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of 61 cents​​ per share for the quarter ended in
June. The mean expectation of eleven analysts for the quarter
was for a loss of 72 cents per share.
    * Revenue rose 239.7% to $6.08 million from a year ago;
analysts
expected $5.73 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 61 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Marinus Pharmaceuticals Inc shares had fallen by 20.1%
this
quarter and gained 118.1% so far this year.
    * The company reported a quarterly loss of $31.93 million.
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $22.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 03:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.72          -0.61          Beat
 Mar. 31 2023      -0.72          -0.67          Beat
 Dec. 31 2022      -0.70          -0.76          Missed
 Sep. 30 2022      0.47           -0.94          Missed